EN | TR
E-ISSN: 2149-6447
FDG PET/CT Imaging for Evaluation of Treatment Response in Lung Cancer
PDF
Cite
Share
Request
Review
VOLUME: 4 ISSUE: 1
P: 43-51
March 2018

FDG PET/CT Imaging for Evaluation of Treatment Response in Lung Cancer

Nucl Med Semin 2018;4(1):43-51
DOI: 10.4274/nts.2018.007
İnanç Karapolat
1. Özel Kent Hastanesi, Nükleer Tıp Kliniği, İzmir, Türkiye
No information available.
No information available
Publish Date: 27.03.2018
PDF
Cite
Share
Request

ABSTRACT

Lung cancer is the most common cause of cancer-related mortality worldwide. Surgery, radiation therapy, systemic chemotherapy, and biological therapy are the modalities used to treat lung cancer. Despite recognized limitations, structural imaging with computed tomography (CT) remains the standard technique for evaluating the response of lung cancer to both chemotherapy and radiotherapy. Metabolic imaging with positron emission tomography/computed tomography (PET/CT) using F-18 fluoro-2-deoxy-glucose (FDG) shows difference in monitoring the tumor response to therapy by integrating anatomic and functional measures of treatment effects. The high uptake of F-18 FDG in most lung cancers and the demonstration that successful treatment reduces uptake have led to increasing enthusiasm for the use of PET/CT to assess the therapeutic response. In this review, theoretic considerations and current evidence supporting the role of F-18 FDG PET/CT for evaluation of treatment response in lung cancer are discussed.